ENVERIC BIOSCIENCES INC (ENVB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.40-4.11%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ENVB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ENVB — debt issuance
Dated 2026-06-09
Other Events. On June 9, 2026, Enveric Biosciences, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) to offer an additional $2,425,000 of shares (the “Shares”) of its common stock, par value $0.01 per share (“Common Stock”), issuable pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC (the “Sales Agent”), dated April 9, 2025 (the “ATM Agreement”). Prior to the date hereof, the Company has sold an aggregate of $4,4…
Why it matters: The filing is the next step toward human testing. FDA clearance would let Enveric start its planned Phase 1 trial.
Supportive ifThe FDA accepts the EB-003 IND, and Enveric reports clearance to begin the Phase 1 trial.
Worry ifEnveric reports a delay in the IND filing, an FDA hold, or a request for more safety data.
Why it matters: Enveric reported $8.3 million in cash and ongoing losses. New funding may affect how long it can advance EB-003.
Worry ifThe Nov. 13 update reports cash above $8.3 million, with new funds raised and no larger quarterly loss than $3.0 million.
Less concerning ifThe update reports cash below $8.3 million, no new funds, or a quarterly loss above $3.0 million.
Why it matters: A granted patent would add protection for another drug series. A rejection or narrower claim may limit that protection.
Supportive ifThe USPTO grants a patent for the EVM401 Series application listed in the Notice of Allowance.
Worry ifThe USPTO withdraws the allowance, rejects the application, or grants claims that omit key compounds.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$208 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $1,077 loss on $10,000 · 10.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,771 loss on $10,000 · 87.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.